AGENUS INC (AGEN)
Health Care · Biotechnology · NASDAQ
A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term revenue through royalty sales and partnerships.
What AGENUS INC does
Agenus Inc is a biopharmaceutical company focused on the development of immuno-oncology product candidates, with botensilimab as its lead therapeutic targeting cancer indications. The company is advancing combination therapy programs alongside its lead program and has expanded its revenue through non-cash royalty revenue from the sale of future royalties and milestones related to prior partnerships. Agenus maintains equity method investments in related entities and generates pre-commercial product revenue from early-stage commercialization efforts.
Themes: immuno-oncology / checkpoint inhibitors, cancer immunotherapy, clinical-stage therapeutics, combination therapies, Immuno-oncology / checkpoint inhibitors
Fundamentals
- Price$8.09 as of 2026-08-21 close
- Market cap$364M as of 2026-08-21
- 1-year return+77.0% 2025-08-21 close $4.57 → 2026-08-21 close $8.09
- P/E4.88 as of 2026-08-24
- Net margin+52.2% as of 2026-08-24
- Gross margin+99.3% as of 2026-08-24
- ROE+76.6% as of 2026-08-24
- Debt / equity4.01 as of 2026-08-24
- Revenue growth (YoY)+24.5% as of 2026-08-24
- Revenue CAGR (3y)+5.2% SEC XBRL
- Beta1.40 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How AGEN compares in its sector
- price-to-earnings ratiobottom 10% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AGENUS INC looks technically
AGENUS INC (AGEN) is trading 100.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 54, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day high about 14 trading days ago. Trading volume is unusually light — only about 19% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 100.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +100.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.29 | $5.29 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.05 | $4.05 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 6.36. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal | 20 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 100.0% above | +100.0% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 54, with buyers in control | 53.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 63.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($6.36 to $8.84) — its "stochastic" reading is 70 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 69.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.84 | $8.84 |
|---|---|---|
| From the 52-week high | it is 8.5% below its 52-week high (its highest price of the past year) | -8.5% |
| Above the 52-week low | it is 198.5% above its 52-week low (its lowest price of the past year) | +198.5% |
| Below the 52-week high | it is 8.5% below its highest point of the past year | 8.5% |
| Since a 20-day breakout | it made a new 20-day high about 14 trading days ago | 14 sessions |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $847.72 (set on 2006-02-17) | $847.72 |
| Given back of the 52-week move | over the past year its closes ranged ($2.77 to $8.30), and it has given back only a small part of its rise from last year’s low — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.71 to $4.88. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.8% |
| From the all-time high | it is 99.0% below its all-time high | -99.0% |
| Nearest price level | it is trading 19.0% above a support level at $6.55 — a price it turned at twice since 2024-09-17, most recently on 2025-07-28. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -19.0% |
| All-time low | its lowest closing price on record is $1.38 (set on 2025-04-07) | $1.38 |
| Above the all-time low | it is 486.2% above its all-time low | +486.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 37th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7027 between its high and its low — about 8.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7027 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.19 and $8.48 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.19 – $7.33 – $8.48 |
| Typical daily range (% of price) | its price moves about 8.7% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.7% |
| Stretch from the 200-day average | it is trading 5.8 daily ranges above its 200-day average price (100.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 19% of its 30-day average | 0.19× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 11.4% since the prior reading | -11.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.2% |
|---|---|---|
| Open gap | it gapped 61.8% above the previous close 29 sessions ago and has not traded back through the level it left behind at 3.35 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +61.8% |
| Gap filled | a 2.9% gap down opened on 2026-08-11 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 7 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 42.7 percentage points (the stock gained 45.0% while the market gained 2.3%) | +42.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 152.9 percentage points (the stock gained 156.0% while the market gained 3.1%) | +152.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 153.3 percentage points (the stock gained 164.4% while the market gained 11.1%) | +153.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 56.5 percentage points (the stock gained 77.0% while the market gained 20.5%) | +56.5% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 39% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.8% of the share price, which is taken to mean a barrier that gives way easily. | +38.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 49% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.42 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +49.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% above the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $7.42 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +9.1% |
Price levels it has turned at before
AGEN last closed at $8.09 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.55 | Support | 19.0% below the last close | turned there twice · 2024-09-17 to 2025-07-28 |
| $6.36 | Support | 21.4% below the last close | turned there twice · 2025-06-06 to 2026-08-10 |
| $4.83 | Support | 40.2% below the last close | turned there twice · 2025-09-22 to 2026-01-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $6.36.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $12.35 and $16.05 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $6.36.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · in a strong, established uptrend (ADX) · Analyst price target recently CUT · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 2 analysts
- Mean price target$19.50 range $14.00 – $25.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AGEN
- Consensus EPS estimate$0.04 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Going concern warning from auditors and historical net losses with continued losses anticipated, creating significant financial and operational risk.","Botensilimab and combination programs are highly dependent on successful clinical development; failure to advance these candidates or encounter adverse events could halt pipeline progression.","Limited resources create strain on ability to simultaneously advance multiple product candidates and successfully bring programs to regulatory approval and commercialization."]
What changed in the latest 10-Q
AI-assisted comparison of AGEN's 10-Q filed 2026-05-11 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K for fiscal year ended December 31, 2025 (instead of 2024)
- Removed 'MiNK' from trademark statement in newer filing
- Added description of Q1 2026 developments: physician engagement expansion, BATTMAN trial enrollment, Zydus collaboration closing, SEC investigation conclusion, and securities class action dismissal
- Added information about BOT/BAL availability in France under AAC framework with specific indications (MSS metastatic colorectal cancer, platinum-resistant/refractory ovarian cancer, soft-tissue sarcomas) and reimbursement details
- Added named-patient programs availability outside France through treating physicians
- Added appointment of BAP Pharma as global distribution partner in April 2026
- Added details about global Phase 3 BATTMAN trial: commencement in April 2026, approximately 830 patients, MSS/pMMR metastatic colorectal cancer, 100+ sites in Canada, France, Australia and New Zealand
- Added Zydus Lifesciences Ltd. strategic collaboration details: $91.0 million cash at closing ($75.0 million for manufacturing facilities, $16.0 million equity investment), exclusive license for India and Sri Lanka, royalties eligibility, up to $50.0 million contingent payments, $20.0 million triggered in March 2026
- Added statement regarding intent to seek Accelerated Approval in US and Conditional Approval in EU for BOT/BAL in 2026
- Added SEC investigation conclusion dated May 4, 2026 with no enforcement action recommendation
- Added District Court dismissal of securities class action on March 24, 2026 with notice of appeal filed
- Removed:
- Removed detailed description of company as 'vertically integrated biotechnology company' with integrated end-to-end capabilities
- Removed specific description of antibody discovery platforms and proprietary display technologies
- Removed detailed pipeline description including saponin-based vaccine adjuvant platform specifics
- Removed reference to iNKT therapies and MiNK controlled pipeline description
- Removed discussion of regular evaluation of development, commercialization, and partnering strategies
- Removed April 2023 Fast Track designation details for BOT/BAL
- Removed description of trial designs for MSI-H/dMMR metastatic colorectal cancer
- Removed statement about registration-enabling trials launching upon completion of strategic transactions
- Removed statement about options being considered (partnerships, licensing, joint ventures)
- Removed list of collaborations with BMS, Betta, UroGen, Gilead, Incyte, and Merck
- Removed detailed information about Incyte collaboration terminations (OX40, GITR, undisclosed programs, LAG-3, TIM-3) and reversion of rights
- Reworded:
- Changed from 'We are a clinical-stage biotechnology company specializing in discovering and developing therapies' to 'Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies'
- Changed overview focus from broad pipeline description to specific emphasis on lead program BOT/BAL and I-O focus
- Changed description of primary business from general I-O to specific antibody-based programs to activate innate and adaptive immunity and overcome tumor immune evasion
- Changed MiNK description from adoption cell therapies pipeline component to equity investment with specific fair value ($22.9 million as of March 31, 2026)
- Changed SaponiQx description from vaccine adjuvant platform component to majority ownership of vaccine adjuvant business
- Notes:
- Newer filing text appears truncated at end ('Botensilimab is a multifunctional ant'), making complete comparison impossible for content beyond that point
- Older filing text also appears truncated at end ('Pursuant to our collaboration and license agreement wi'), limiting full section comparison
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for AGEN — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AGEN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,122,400
- Reported value $3,748,816
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AGEN had 6,232,820 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AGEN had 13.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.05 days to cover at the same settlement.
- Reported short interest (shares) 6,232,820
- Short interest (% of shares outstanding) 13.8%
- Prior settlement (shares) 7,057,525
- Reported change -11.69%
- Days to cover (reported) 3.05
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bristol Myers Squibb (BMY)
- Merck (MRK)
- Roche (RHHBY)
- AstraZeneca (AZN)
- GSK (GSK)
- Regeneron Pharmaceuticals (REGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AGEN vs…
AGEN ranks in…
Frequently asked questions
What does AGENUS INC (AGEN) do?
Agenus Inc is a biopharmaceutical company focused on the development of immuno-oncology product candidates, with botensilimab as its lead therapeutic targeting cancer indications. The company is advancing combination therapy programs alongside its lead program and has expanded its revenue through non-cash royalty revenue from the sale of future royalties and milestones related to prior partnerships.
What sector is AGENUS INC (AGEN) in?
AGENUS INC (AGEN) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are AGENUS INC's (AGEN) competitors?
Notable peers of AGENUS INC (AGEN) include Bristol Myers Squibb, Merck, Roche, AstraZeneca and GSK. This peer set is informational only — not financial advice.
Is AGENUS INC (AGEN) overbought or oversold right now?
AGENUS INC (AGEN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AGEN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.